Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary
SEC Form 4 Filing
Agenus Inc. CEO Garo H. Armen received 3,080 shares of common stock in lieu of cash salary for the pay period ending April 19, 2024, while also disposing of 69,797 shares.
Summary
- Garo H. Armen, CEO of Agenus Inc., received 3,080 shares of Agenus common stock on April 19, 2024, as compensation in lieu of cash salary.
- The stock was issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and was fully vested upon issuance.
- The price of the stock was $5.31 per share, which was the closing price of Agenus common stock on April 19, 2024.
- Armen also indirectly owns 31,298 shares through his IRA accounts and 28,950 shares as trustee and general partner.
- He disposed of 69,797 shares of common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment. The CEO taking stock in lieu of salary could be seen as positive, but the disposal of shares is a negative.
Positives
- The CEO's decision to take salary in stock may signal confidence in the company's future performance.
Negatives
- The disposal of 69,797 shares by the CEO could be interpreted negatively by investors.
Risks
- The Form 4 filing indicates a change in beneficial ownership, which could lead to investor speculation and potential market volatility.
Industry Context
Stock compensation is a common practice for aligning management interests with shareholder value, particularly in growth-oriented companies. The CEO taking stock in lieu of cash is not uncommon in the biotech industry.
Comparison to Industry Standards
- Comparing Agenus's executive compensation structure to companies like Immunomedics (acquired by Gilead), or Adaptimmune, which also operate in the immunotherapy space, would provide a benchmark.
- Executive compensation packages often include a mix of salary, stock options, and performance-based bonuses.
- The percentage of compensation delivered in stock versus cash can vary widely based on company size, stage of development, and overall financial health.
Stakeholder Impact
- Shareholders may view the CEO accepting stock in lieu of cash as a positive sign of confidence.
- Employees may see this as a commitment from leadership to the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 04/19/2024 | Date of the transaction where Garo H. Armen received stock in lieu of cash salary. |
| 04/19/2024 | Payroll date for the pay period ending on this date. |
| 04/22/2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.